MA50657A - Formulations de niraparib - Google Patents

Formulations de niraparib

Info

Publication number
MA50657A
MA50657A MA050657A MA50657A MA50657A MA 50657 A MA50657 A MA 50657A MA 050657 A MA050657 A MA 050657A MA 50657 A MA50657 A MA 50657A MA 50657 A MA50657 A MA 50657A
Authority
MA
Morocco
Prior art keywords
niraparib formulations
niraparib
formulations
Prior art date
Application number
MA050657A
Other languages
English (en)
Inventor
Simon Mcgurk
Padma Narayan
Aleksandar Rajlic
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63858161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50657(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of MA50657A publication Critical patent/MA50657A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA050657A 2017-09-26 2018-09-26 Formulations de niraparib MA50657A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762563535P 2017-09-26 2017-09-26

Publications (1)

Publication Number Publication Date
MA50657A true MA50657A (fr) 2020-08-05

Family

ID=63858161

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050657A MA50657A (fr) 2017-09-26 2018-09-26 Formulations de niraparib

Country Status (18)

Country Link
US (2) US11730725B2 (fr)
EP (1) EP3687505A1 (fr)
JP (1) JP7269227B2 (fr)
KR (2) KR20250016494A (fr)
CN (1) CN111278433A (fr)
AU (2) AU2018341479B2 (fr)
BR (1) BR112020006039A2 (fr)
CA (1) CA3076907A1 (fr)
CL (1) CL2020000747A1 (fr)
EA (1) EA202090573A1 (fr)
IL (1) IL273282A (fr)
MA (1) MA50657A (fr)
MX (1) MX2020003760A (fr)
MY (1) MY209708A (fr)
PH (1) PH12020550341A1 (fr)
SG (1) SG11202002113TA (fr)
TW (1) TWI843707B (fr)
WO (1) WO2019067634A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811564QA (en) 2016-06-29 2019-01-30 Tesaro Inc Methods of treating ovarian cancer
EP3600314A1 (fr) 2017-03-27 2020-02-05 Tesaro, Inc. Compositions de niraparib
CN118271233A (zh) 2017-04-24 2024-07-02 特沙诺有限公司 尼拉帕利的制造方法
US12156872B2 (en) 2017-05-09 2024-12-03 Tesaro, Inc. Combination therapies for treating cancer
CA3063715A1 (fr) 2017-05-18 2018-11-22 Tesaro, Inc. Polytherapies pour le traitement du cancer
CA3076907A1 (fr) 2017-09-26 2019-04-04 Tesaro, Inc. Formulations de niraparib
CN111372607A (zh) 2017-09-30 2020-07-03 特沙诺有限公司 用于治疗癌症的联合疗法
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
UY39204A (es) * 2020-05-08 2021-11-30 Janssen Pharmaceutica Nv Formulaciones farmacéuticas de acetato de abiraterona y niraparib
JP7797425B2 (ja) * 2020-06-19 2026-01-13 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド ダプロデュスタットを含んでなる処方物
US12059419B2 (en) * 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
EP4247351A4 (fr) * 2020-11-20 2024-10-23 Tsirikos-Karapanos, Nikolaos Formulation de chlorure d'ammonium d'aide à la défense naturelle humaine contre des virus
CN119156216A (zh) 2022-02-15 2024-12-17 特沙诺有限公司 尼拉帕尼用于治疗脑癌的用途
EP4629971A1 (fr) * 2022-12-09 2025-10-15 Olema Pharmaceuticals, Inc. Formes galéniques d'un antagoniste du récepteur des estrogènes
WO2025037251A1 (fr) * 2023-08-14 2025-02-20 Glenmark Life Sciences Limited Dispersions solides de niraparib ou d'un sel pharmaceutiquement acceptable de celui-ci
IT202300022608A1 (it) * 2023-10-27 2025-04-27 O3 Zone Ltd Formulazione granulare comprendente olio ozonizzato, relativo metodo di preparazione, forme farmaceutiche comprendenti detta formulazione granulare e loro usi.
CN119909081B (zh) * 2025-01-20 2025-12-05 湖南新汇制药股份有限公司 一种抑制卵巢癌的组合物、纳米颗粒、制备方法和应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606337D0 (en) 1996-03-26 1996-05-29 Freeman Reginald E Rheometer
AR030630A1 (es) 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
HUE039584T2 (hu) 2004-10-29 2019-01-28 Kalypsys Inc PPAR-modulátor szulfonil-szubsztituált biciklusos vegyületek
GB0700432D0 (en) 2007-01-10 2007-02-21 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2647545C (fr) 2006-04-03 2016-02-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Utilisation de derives de benzotriazole et d'indazole amide substitue comme inhibiteurs de la poly(adp-ribose)polymerase (parp)
GB0606663D0 (en) 2006-04-03 2006-05-10 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008043024A2 (fr) * 2006-10-04 2008-04-10 Kalypsys, Inc. Formulation pharmaceutique orale comprenant un sulfonyle bicyclique modulateur de ppar pour le traitement d'une maladie
CA2563690C (fr) * 2006-10-12 2014-10-07 Pharmascience Inc. Compositions pharmaceutiques comprenant des fractions intra- et extra- granulaires
EP2805945B1 (fr) 2007-01-10 2019-04-03 MSD Italia S.r.l. Indazoles substitués d'amide en tant qu'inhibiteurs PARP de poly(ADP-ribose)polymérase
RU2481830C2 (ru) 2007-01-16 2013-05-20 Бипар Сайенсиз, Инк. Лекарственные препараты для лечения рака
JP5593229B2 (ja) 2007-10-17 2014-09-17 クドス ファーマシューティカルズ リミテッド ４−［３−（４−シクロプロパンカルボニル−ピペラジン−１−カルボニル）−４−フルオロ−ベンジル］−２ｈ−フタラジン−１−オン
JP5989965B2 (ja) 2008-01-08 2016-09-07 メルク シャープ エンド ドーム リミテッド ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
CN102482282A (zh) 2009-08-26 2012-05-30 赛福伦公司 多环化合物的新形式
CA2779052A1 (fr) 2012-05-31 2013-11-30 Pharmascience Inc. Composition pharmaceutique d'antecavir et processus de fabrication
US9738915B2 (en) 2012-12-07 2017-08-22 Merck Sharp & Dohme Corp. Biocatalytic transamination process
US9580407B2 (en) 2012-12-07 2017-02-28 Merck Sharp & Dohme Corp. Regioselective N-2 arylation of indazoles
CN105492011A (zh) * 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
KR102243062B1 (ko) 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
US9191894B2 (en) 2013-07-23 2015-11-17 Disney Enterprises, Inc. Power saving for multi-hop communications
CA2935857C (fr) * 2014-01-05 2020-12-15 Washington University Traceurs radiomarques pour la poly (adp-ribose) polymerase-1 (parp-1), leurs procedes et utilisations
JP6500037B2 (ja) 2014-04-22 2019-04-10 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 二環式ピラゾロン化合物および使用方法
WO2015164586A1 (fr) * 2014-04-23 2015-10-29 The Brigham And Women's Hospital, Inc. Ciblage de parp1 pour le traitement de la sclérose tubéreuse de bourneville et de cancers
US10238630B2 (en) 2014-05-28 2019-03-26 Eisai R&D Management Co., Ltd. Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
DK3182975T3 (da) * 2014-08-22 2025-10-20 Pharma& Schweiz Gmbh Tabletter med høj doseringsstyrke af rucaparib
EP3230472A4 (fr) 2014-12-08 2018-06-13 Myriad Genetics, Inc. Méthodes et matériaux permettant de prédire une réaction au niraparib
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
CN107847589B (zh) 2015-04-01 2022-03-29 安奈普泰斯生物有限公司 针对t细胞免疫球蛋白和粘蛋白蛋白3(tim-3)的抗体
SI3892302T1 (sl) 2015-04-06 2023-11-30 Janssen Pharmaceutica Nv Sestavki, ki vsebujejo ibrutinib
DK3954690T3 (da) 2015-07-02 2023-06-06 Acerta Pharma Bv Faste former og formuleringer af (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamid
AU2016303489B2 (en) 2015-07-31 2023-02-16 University Of Florida Research Foundation, Inc. Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
WO2017125423A1 (fr) 2016-01-19 2017-07-27 Janssen Pharmaceutica Nv Formulations/compositions comprenant un inhibiteur de btk
US20190133980A1 (en) 2016-06-02 2019-05-09 Yale University Compositions and methods for targeting and treating homologous recombination-deficient tumors
SG11201811564QA (en) 2016-06-29 2019-01-30 Tesaro Inc Methods of treating ovarian cancer
CN106496187A (zh) 2016-09-14 2017-03-15 陕西科技大学 一种制备PARP抑制剂Niraparib的合成方法
EP3666794A1 (fr) 2016-11-01 2020-06-17 AnaptysBio, Inc. Anticorps dirigés contre la mort programmée 1 (pd -1)
BR112019008861A2 (pt) 2016-11-01 2019-07-09 Tesaro, Inc. anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3)
CN106831708A (zh) 2016-11-22 2017-06-13 西安泰科迈医药科技股份有限公司 一种新型口服抗癌药物Nirapairb的合成方法
CN108201537A (zh) 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种尼拉帕尼缓控释药物组合物及其用途
CN106854176A (zh) 2016-12-21 2017-06-16 南京艾德凯腾生物医药有限责任公司 一种制备尼拉帕尼对甲苯磺酸盐一水合物的方法
WO2018122168A1 (fr) * 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinaisons d'inhibiteurs de kinase bub1 et d'inhibiteurs de parp
BR112019014187A2 (pt) 2017-01-09 2020-02-11 Tesaro, Inc. Métodos de tratamento de câncer com anticorpos anti-pd-1
SG10201913083SA (en) 2017-01-09 2020-03-30 Tesaro Inc Methods of treating cancer with anti-tim-3 antibodies
EP3600314A1 (fr) 2017-03-27 2020-02-05 Tesaro, Inc. Compositions de niraparib
BR112019020191A2 (pt) 2017-03-27 2020-04-22 Tesaro Inc formulações de niraparib
CN118271233A (zh) 2017-04-24 2024-07-02 特沙诺有限公司 尼拉帕利的制造方法
SG10201913677SA (en) 2017-04-27 2020-03-30 Tesaro Inc Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
US12156872B2 (en) 2017-05-09 2024-12-03 Tesaro, Inc. Combination therapies for treating cancer
CA3063715A1 (fr) 2017-05-18 2018-11-22 Tesaro, Inc. Polytherapies pour le traitement du cancer
CN108530425A (zh) 2017-05-27 2018-09-14 广州科锐特生物科技有限公司 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法
CA3076907A1 (fr) 2017-09-26 2019-04-04 Tesaro, Inc. Formulations de niraparib
CN111372607A (zh) 2017-09-30 2020-07-03 特沙诺有限公司 用于治疗癌症的联合疗法
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
EP3731866A1 (fr) 2017-12-27 2020-11-04 Tesaro Inc. Méthodes de traitement du cancer
CA3090479A1 (fr) 2018-02-05 2019-08-08 Tesaro, Inc Formulations pediatriques de niraparib et procedes de traitement pediatrique

Also Published As

Publication number Publication date
US11730725B2 (en) 2023-08-22
JP2020535158A (ja) 2020-12-03
KR20250016494A (ko) 2025-02-03
EP3687505A1 (fr) 2020-08-05
WO2019067634A1 (fr) 2019-04-04
TWI843707B (zh) 2024-06-01
EA202090573A1 (ru) 2020-09-07
CL2020000747A1 (es) 2020-09-25
MX2020003760A (es) 2020-07-29
TW201927304A (zh) 2019-07-16
JP7269227B2 (ja) 2023-05-08
US20200289494A1 (en) 2020-09-17
CA3076907A1 (fr) 2019-04-04
KR20200058496A (ko) 2020-05-27
AU2018341479A1 (en) 2020-04-16
BR112020006039A2 (pt) 2020-10-06
PH12020550341A1 (en) 2021-02-15
SG11202002113TA (en) 2020-04-29
CN111278433A (zh) 2020-06-12
AU2018341479B2 (en) 2022-02-17
IL273282A (en) 2020-04-30
US20240082231A1 (en) 2024-03-14
AU2022200520A1 (en) 2022-02-17
MY209708A (en) 2025-07-31

Similar Documents

Publication Publication Date Title
IL268697A (en) Formulations
DK3688162T3 (da) Formuleringer
DK3731771T3 (da) V462033dk00
MA50657A (fr) Formulations de niraparib
CL2018000524S1 (es) Golilla
EP3589248A4 (fr) Cryothérapies
DE202018003363U8 (de) Handgelenkssphygmomanometer
EP3634404C0 (fr) Inhibiteurs de magl à base de pyrazole
EP3588580A4 (fr) Diode schottky mos à tranchée
DK3351526T3 (da) Diisopentylterephthalat
EP3580321A4 (fr) Compositions de nettoyage
EP3654852A4 (fr) Garrot
EP3634397A4 (fr) Chromophores ir à base de polyméthine hétérocyclyle
PL3703518T3 (pl) Formulacja ulegająca aerozolowaniu
DK3568655T3 (da) Rekuperator
EP3364945C0 (fr) Formulation solide
DK3571580T5 (da) Load-logical-and-shift-guarded-instruktion
DK3651736T3 (da) Langtidsvirkende formuleringer
DK3612237T3 (da) Genterapi
EP3611402A4 (fr) Servocylindre
EP3697418A4 (fr) Formulations de bromocriptine améliorées
MA50068A (fr) Formulations de copanlisib
DK3709970T3 (da) Linezolidformuleringer
IL272167A (en) Hemopexin formulations
DK3576686T3 (da) Brokbind